BIOASIS
TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or
“Bioasis”), a pre-clinical, research-stage biopharmaceutical company
developing its proprietary xB3™ platform technology for the
delivery of therapeutics across the blood-brain barrier (“BBB”) and the
treatment of central nervous system (“CNS”) disorders in areas of high
unmet medical need, including brain cancers and neurodegenerative
diseases, today announced that Dr. Deborah Rathjen, Executive Chair and
Chief Executive Officer of Bioasis will present at the following
industry conferences:
3rd Annual Neuroscience Innovation Forum for
Business Development, Licensing and Investment. (https://www.sachsforum.com/3nif-about.html)
-
Bioasis company presentation on Sunday, January 12, 2020 at 11:25am PT
in the Regimental room at the Marines’ Memorial Club & Hotel, San
Francisco.
-
Rare and Orphan Diseases Panel on Sunday, January 12, 2020 at 2:10pm
PT in the Commandants room.
Biotech ShowcaseTM. (https://informaconnect.com/biotech-showcase/)
-
Bioasis company presentation on Monday, January 13, 2020 at 9:00am PT
in the Franciscan A room, Ballroom level, at the Hilton San Francisco
Union Square, San Francisco.
-
Bioasis company presentation will be followed at 11:20am PT on Monday,
January 13, 2020 by an interview with Proactive Investors.
Follow us on:
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company developing the
xB3 ™ platform, a proprietary technology for the delivery of
therapeutics across the blood brain barrier and the treatment of CNS
disorders in areas of high unmet medical need, including brain cancers
and neurodegenerative diseases. The delivery of therapeutics across the
blood brain barrier represents the final frontier in treating
neurological disorders. The in-house development programs at Bioasis are
designed to develop symptomatic and disease-modifying treatments for
brain-related diseases and disorders. The company maintains headquarters
in Guilford, Conn., United States. Bioasis trades on the TSX Venture
Exchange under the symbol “BTI” and on the OTCQB under the symbol
“BIOAF.” For more information about the company, please visit www.bioasis.us.
Forward Looking Statements
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including the Company’s intended use of proceeds of the Bridge
Financing, along with other statements containing the words “believe”,
“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”,
“expect” and similar expressions. Such forward-looking statements or
information involve known and unknown risks, uncertainties and other
factors that may cause our actual results, events or developments, or
industry results, to be materially different from any future results,
events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage
of development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical trials and
obtaining regulatory approval to market our products, the ability to
protect our intellectual property, dependence on collaborative partners
and the prospects for negotiating additional corporate collaborations or
licensing arrangements and their timing. Specifically, certain risks and
uncertainties that could cause such actual events or results expressed
or implied by such forward-looking statements and information to differ
materially from any future events or results expressed or implied by
such statements and information include, but are not limited to, the
risks and uncertainties that: products that we develop may not succeed
in preclinical or clinical trials, or future products in our targeted
corporate objectives; our future operating results are uncertain and
likely to fluctuate; we may not be able to raise additional capital; we
may not be successful in establishing additional corporate
collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be
greater than anticipated; we have no experience in commercial
manufacturing; we may face unknown risks related to intellectual
property matters; we face increased competition from pharmaceutical and
biotechnology companies; and other factors as described in detail in our
filings with the Canadian securities regulatory authorities at www.sedar.com.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update
such forward- looking statements and information to reflect subsequent
events or circumstances, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005926/en/
Copyright Business Wire 2020